Skip to main content

Table 1 Clinical and biologic characteristics of the patients in two cohorts

From: Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas

Variables Training cohort (n = 115) Validation cohort (n = 58) P-value
Basic results
 Age, years 54 (43.0, 65.0) 52 (45.8, 61.2) 0.611
 Sex (%)
  Female 35 (30.4) 19 (32.8) 0.755
  Male 80 (69.6) 39 (67.2)
 Subtype composition
  ENKTL 40 (34.8) 24 (41.4) 0.037
  PTCL-NOS 32 (27.8) 14 (24.1)
  AITL 25 (21.7) 4 (6.9)
  ALCL 8 (7.0) 11 (19.0)
  EATCL 6 (5.2) 2 (3.4)
  MF/SPTCL 4 (3.5) 3 (5.2)
 ECOG score (%)
  < 2 62 (53.9) 38 (65.5) 0.145
  ≥ 2 53 (46.1) 20 (34.5)
 BM involvement (%)
  Absence 86 (74.8) 47 (81.0) 0.357
  Presence 29 (25.2) 11 (19.0)
 Extranodal sites (%)
  < 2 61 (53.0) 32 (55.2) 0.791
  ≥ 2 54 (47.0) 26 (44.8)
 Ann Arbor stage (%)
  I/II 44 (38.3) 25 (43.1) 0.539
  III/IV 71 (61.7) 33 (56.9)
 B symptoms (%)
  Absence 41 (35.7) 27 (46.6) 0.166
  Presence 74 (64.3) 31 (53.4)
Serological results
 LDH, U/L 243.0 (183.6, 388.0) 224.3 (178.9, 320.6) 0.433
 Β2-MG, mg/L 3.0 (2.2, 3.8) 2.8 (2.2, 3.6) 0.424
 TC, mmol/L 4.0 (3.2, 4.7) 4.1 (3.5, 5.1) 0.087
 HDL-C, mmol/L 1.0 (0.8, 1.2) 1.1 (0.9, 1.3) 0.041
 TG, mmol/L 1.3 (1.0,1.7) 1.2 (0.8,1.8) 0.375
Clinical scoring systems
 IPI (%)
  Low risk 45 (39.1) 24 (41.4) 0.819
  Low-intermediate risk 13 (11.3) 9 (15.5)
  Intermediate-high risk 25 (21.8) 11 (19.0)
  High risk 32 (27.8) 14 (24.1)
Treatment
 Therapy (%)
  CT alone 60 (52.2) 17 (29.3) 0.014
  RT alone 8 (6.9) 4 (6.9)
  CT + RT 18 (15.7) 13 (22.4)
  CT + HDACi 21 (18.3) 22 (37.9)
  CT + HSCT 8 (6.9) 2 (3.5)
Outcomes
 Therapeutic response (%)
  CR/PR 30 (26.1) 24 (41.4) 0.040
  SD/PD 85 (73.9) 34 (58.6)
  Death (%) 67 (58.3) 16 (27.6) 0.000
  Median OS 21.0 (9.0, 55.0) 13.5 (5.4, 17.0) 0.000
  Progression and NRM (%) 78 (67.8) 26 (44.8) 0.004
  Median PFS 12.0 (3.5, 41.0) 9.8 (3.9, 15.6) 0.038
  1. ENKTL extranodal NK/T-cell lymphoma, PTCL-NOS peripheral T-cell lymphoma, not otherwise specified, AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, EATCL enteropathy-associated T-cell lymphoma, MF mycosis fungoides, SPTCL subcutaneous panniculitis-like T-cell lymphoma, ECOG Eastern Cooperative Oncology Group, BM bone marrow, LDH lactate dehydrogenase, β2-MG beta-2 microglobulin, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, IPI International Prognostic Index, CT chemotherapy, RT radiotherapy, HDACi histone deaceylase inhibitor, HSCT hematopoietic stem cell transplantation, CR complete response, PR partial response, SD stable disease, PD progressive disease, OS overall survival, NRM non-relapse mortality, PFS progression-free survival